maria jose vargas

[Mayo Clinic Nephrology @MayoClinicNeph]

Contactin-1 Membranous Nephropathy Without Neuropathy and Serum Antibodies

@KIReports @fervenzaf @SethiRenalPath

https://t.co/dZBmCLWPZZ

[Mayo Clinic Nephrology @MayoClinicNeph]

Artificial Intelligence in Rare Diseases: Workflow-Integrated Precision Kidney Care

Charat Thongprayoon, Francesco Pesce, Wisit Cheungpasitporn 

@FrancescoPesce @wisit661

https://t.co/hGttscbbEY

[Mayo Clinic Nephrology @MayoClinicNeph]

Accelerating Mechanistic Biomarker Discovery in Antibody-mediated Rejection Through Spatial Transcriptomics

@MPAlexanderMD

https://t.co/IpDRHMYy6G

[Sandra Herrmann MD, FASN @HerrmannMd]

Congratulations Dr @fervenzaf and team: Obinituzumab vs Tacrolimus for MN @NEJM @MayoClinicNeph 👏👏

[NEJM @NEJM]

Presented at #ERA26:

In this 104-week trial involving patients with primary membranous nephropathy, the type II anti-CD20 antibody obinutuzumab was superior to the calcineurin inhibitor tacrolimus in inducing complete remission. Full phase 3 MAJESTY trial results: https://t.co/T3Z8pTEARK

@ERAkidney

[Mayo Clinic Nephrology @MayoClinicNeph]

😊👏👏 Prof. Fernando Fervenza presenting the Phase III MAJESTY Trial at the Late Breaking Clinical Trials #ERA2026. Trial compared obinutuzumab vs tacrolimus in primary membranous Nephropathy & highlighted advances in glomerular disease care @ERAkidney @fervenzaf #ERA26

[Mayo Clinic Nephrology @MayoClinicNeph]

Wonderful presentation by Dr. Sandra Herrmann at #ERA2026 on “Biomarker-Driven Immunotherapy for Checkpoint Inhibitor–Induced Interstitial Nephritis.”
@HerrmannMd

[Mayo Clinic Nephrology @MayoClinicNeph]

ERA Glasgow 2026 is happening June 3-6! Join @HerrmannMd on June 4 as she presents on Biomarker-driven Immunotherapy for checkpoint inhibitor-induced interstitial nephritis! #MayoClinicKidney

[Mayo Clinic Nephrology @MayoClinicNeph]

Dr. Fernando Fervenza will be presenting Efficacy and Safety of Obinutuzumab Compared with Tacrolimus in Primary Membranous Nephropathy: Topline Results of the Phase III MAJESTY Trial on June 5th at ERA Congress! #MayoClinicKidney

[Andrea Angioi, MD, FASN @andreaangioi]

Most kidney trials whisper.
This one doesn’t.

@NEJM Phase 3 interim analysis in NEJM:
telitacicept cut proteinuria by 58.9% vs 8.8% placebo in high-risk IgA nephropathy.

eGFR at 39 weeks: -1.0% vs -7.7%.

Dual BAFF/APRIL blockade may be hitting disease upstream.
#IgAN #Nephrology #KidneyDisease #Glomerulonephritis

[Juana Peña @Chris_Montz]

Ha muerto la legendaria Totó la Momposina, una de las figura clave que puso el color y folclor del caribe colombiano en los ojos del mundo!

[Ladan Zand @LadanZand]

Don’t forget to register!

[Priya Alexander, MD @MPAlexanderMD]

1/3
The diagnosis of TMA is challenging. It is really a pattern of injury. What is the etiopathogenesis? How do we treat?

Machine Learning can help.

So thrilled to share this paper, led by
@LadanZand
@MayoClinicNeph @MayoClinicPath https://t.co/EGF1Gti48D

[Sanjeev Sethi @SethiRenalPath]

Difficult but good recent teaching case.

LM- normal appearing glomeruli but proximal tubules filled with eosinophilic granules.

IF- negative.

EM- large number of lysosomes, with degenerative changes.

Lysozyme stain 3+ positive in proximal tubules.

Dx: Lysozyme associated-tubulopathy (myelofibrosis/clinical).

Usually see this in patients with CML.

D/D: light chain proximal tubulopathy, but IF & pronase IF are negative.

60-yr old with chronic kidney disease, pulmonary nodules, and JAK2+ myelofibrosis.

Evaluation showed high levels of serum lysozyme, and lysozymuria.

[Mayo Clinic Nephrology @MayoClinicNeph]

How to Manage an Adult Patient With IgA Nephropathy in the Current Era?

https://t.co/92UyjnLK3h

@LadanZand @fervenzaf @MayoProceedings

[Maria Jose Soler @PepaSolerR]

Lo q no se diagnostica no se trata 👏👏👏👏👏

[NDT @NDTsocial]

Optimal glucocorticoid therapy in lupus nephritis

https://t.co/e6SjmOrRpw

[Sayed S Rahman @SayedSRahman1]

Management of monoclonal gammopathy of renal significance: treatment standard
https://t.co/gWKqHXBSzJ

[Mayo Clinic Nephrology @MayoClinicNeph]

Single-center perspective of glomerular pathology in checkpoint inhibitor-treated patients

@Arjun_Mohan1 @MPAlexanderMD @HerrmannMd @KIReports

https://t.co/kXIp3KI6UF

[Sanjeev Sethi @SethiRenalPath]

Basic evaluation of the kidney biopsy when you see an MPGN on light microscopy.